2020
Authors: Lain MG, Vaz P, Ismael N, Cantarutti A, Porcu G, Palma P, Cotugno N, Bila D, Rinaldi S, Pallikkuth S, Pahwa R, Taibo E, Esmeralda Karajeanes E, Giaquinto C, Pahwa S.
Published in: 27th Conference on Retroviruses and Opportunistic Infections, March 8th –11th, 2020 – Boston.
2020
Authors: Morris SE, Dziobek-Garrett L, Yates AJ and the EPIICAL consortium
Published in: BMC Bioinformatics 2020;21(1):52
Background HIV/AIDS is responsible for the deaths of one million people every year. Although mathematical modeling has provided many insights into the dynamics of HIV infection, there is still a lack of accessible tools for researchers unfamiliar with modeling techniques to apply them to their own clinical data.
2020
Authors: Cotugno N, Morrocchi E, Rinaldi S, et al; EPIICAL Consortium.
Published in: AIDS. 2020 Feb 3.
Objective To investigate long-term persistence of HIV-specific lymphocyte immunity in perinatally HIV-infected children treated within the first year of life.
Design Twenty perinatally HIV-infected children who received ART therapy within the first year of life (early treated) and with stable viral control (>5 years) were grouped according to their serological response to HIV.
2020
Authors: Rinaldi S, Pallikkuth S, Cameron M, et al.
Published in: J Immunol. 2020 Feb 1;204:540-549
Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children limits the size of the virus reservoir, but whether the time of treatment initiation (TI) can durably impact host immune responses associated with HIV infection is still unknown.
2019
Authors: S. Rinaldi, V. Dinh, S. Pallikkuth, L. De Armas, R. Pahwa, N. Cotugno, E. Nastouli, C. Foster, P. Palma, S. Pahwa
Published in: Poster presented at 9th International Workshop on HIV Persistence during Therapy; December, 2019; Miami, FL
Background: Curative strategies for HIV will need to eliminate the replication competent latent reservoir.
2019
Authors: Turner B, Ford D, Moore C, Gibb D, Turkova A, White I, and ODYSSEY trial team
Published in: Oral Presentation atInternational Society for Clinical Biostatics; July 16th 2019
2019
Authors: Domínguez-Rodríguez S, Tagarro A. Palma P, et al.
Published in: JAIDS 2019;82(5):483-490
2019
Authors: Schröter J.
Published in: Poster presented at 4th Workshop on Virus Dynamics, October 21st-23rd, 2019 -Paris, FR
2019
Authors: Gärtner K, Gkouleli T, Heaney J, et al; on behalf of the EPIICAL consortium
Published: Poster presented at HIV Cure and Reservoir Symposium, September, 16th-20th, 2019 -Ghent, BE
2019
Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail Team
Published in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019
2019
Authors: Foster C, Dominguez S, Tagarro A, Nastouli E, Gkouleli R, Heaney J, PalmaP, Rossi P, Giaquinto C, Rojo P
Published: 10th IAS Conference on HIV Science, July 21rd-24th 2019, Mexico City
Background Future strategies aimed at achieving antiretroviral therapy (ART)-free HIV remission are likely to target individuals with a limited size of viral reservoir.
2019
Authors: Heaney J, Busby E, Gärtner K, Grant P, Spyer MJ, O’Sullivan DM, Gkouleli T, Marcelin AG, Pillay D, Foster C, Rojo P, Palma P, Muñoz Fernández MA, deRossi A, Huggett JF, Nastouli E
Published: International Workshop on HIV Pediatrics, July 19th-20th, 2019. P_102
Background Despite effective antiretroviral therapy(ART), HIV persists as integrated provirus generating latent viral reservoirs even in the absence of detectable plasma viremia.
2019
Authors: Colbers A, Bollen P, Freriksen J, Konopnicki D, Weizsäcker K, Hidalgo Tenorio C, Moltó J, Taylor G, Alejandre I, van Crevel R, Burger D; on behalf of the PANNA network
Published: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_758.
2019
Authors: Colbers A, Bollen P, Freriksen J, Konopnicki D, Weizsäcker K, Hidalgo Tenorio C, Moltó J, Taylor G, Alejandre I, van Crevel R, Burger D.
Published: Oral presentation at 9th edition of the International Workshop on HIV & Women, March 2nd-3rd 2019, Seattle
2019
Authors: Kreitchmann R, Schalkwijk S, Best B, et al.
Published in: Antivir Ther. 2019;24(2):95-103
Background Limited data exist on efavirenz pharmacokinetics in HIV-positive pregnant women and neonatal washout.
Methods HIV-infected pregnant women receiving 600 mg efavirenz once daily had intensive steady-state 24-h pharmacokinetics profiles during the second trimester (2T),
2019
Authors: Schalkwijk S, Ter Heine R, Colbers A, et al.
Published in: J Antimicrob Chemother. 2019;30 [Epub ahead of print]
Background Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily combined with low-dose ritonavir is used to treat HIV-positive pregnant women. Decreased total darunavir exposure (17%-50%) has been reported during pregnancy,
2019
Authors: Tagarro A, Dominguez Rodriguez S, Puthanakit T, et al.
Published: Oral presentation at 27th Conference on Retroviruses and Opportunistic Infections, March 4th-7th, 2019 – Seattle, WA
Abstract: Early antiretroviral therapy (ART) in children is associated with better clinical and virological outcome. Few data are available about long-term outcome of children starting ART in the neonatal period.
2019
Authors: Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration.
Published in: Lancet HIV. 2019;6(2):e105-e115.
Background Estimates of incidence of switching to second-line antiretroviral therapy (ART) among children with HIV are necessary to inform the need for paediatric second-line formulations. We aimed to quantify the cumulative incidence of switching to second-line ART among children in an international cohort collaboration.
2019
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
Published in: HIV Med. 2019;20(5):291-307
Objectives Combination neonatal prophylaxis (CNP) is recommended in high‐risk situations for the prevention of mother‐to‐child HIV transmission, although data on its safety are limited. The aim of the study was to identify whether neonatal prophylaxis (NP) type is associated with the risk of severe anaemia or neutropaenia.
2019
Authors: Collins IJ; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
Published in: Clin Infect Dis. 2019; 28. pii: ciz253. doi: 10.1093/cid/ciz253. [Epub ahead of print]
Background In HIV-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality.
2019
Authors: Fidler KJ, Foster C, Lim EJ, et al.; for Collaborative HIV Paediatric Study (CHIPS) Steering Committee
Published in: Pediatr Infect Dis J. 2019;38(2):146-148
Abstract We assessed HIV antibody prevalence in children with perinatally acquired HIV in England. Eighteen percent (10/55) of those starting combination antiretroviral therapy <6 months of age were seronegative at median age 9.1 years and had lower viral load at diagnosis and combination antiretroviral therapy start and fewer viral rebounds,
2019
Authors: Chiappini E, Bianconi M, Dalzini A, et al.
Published in: Antimicrob Resist Infect Control. 2019;8:13
Background Premature aging and related diseases have been documented in HIV-infected adults. Data are now emerging also regarding accelerated aging process in HIV-infected children.
Methods A narrative review was performed searching studies on PubMed published in English language in 2004-2017,
2019
Authors: Bollen P, Turkova A, Mujuru H, et al. for the ODYSSEY Trial Team
Published in: 26th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2019– Seattle. P_830
2019
Authors: Schröter J.
Published: Oral presentation at 26th International HIV Dynamics & Evolution, March 24th-27th, 2019, Cascais, PT
2019
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group
Published in: Aids. 2019;33(2):295-304.
Objectives The aim of this study was to investigate whether specific nucleoside reverse transcriptase inhibitor (NRTI) backbones are associated with risk of adverse pregnancy outcomes among pregnant women starting antiretroviral therapy (ART).
Design Seven observational studies across eight European countries of pregnancies in HIV-positive women.
2019
Authors: Martinez de Tejada B; European Pregnancy and Paediatric HIV Cohort Collaboration Study Group.
Published in: J Acquir Immune Defic Syndr. 2019;80(3):316-324
Background To investigate the association between efavirenz (EFV) use during conception or first trimester (T1) of pregnancy and the occurrence of birth defects.
Setting Seven observational studies of pregnant HIV-positive women across 13 European countries and Thailand.
2019
Authors: Chan MK, Goodall R, Judd A, et al.
Published in: Aids. 2019; 33(7):1155-1165
Objective To identify predictors of faster time to virological suppression among infants starting combination antiretroviral therapy (cART) early in infancy.
Design Cohort study of infants from Europe and Thailand included in studies participating in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC).
2018
Authors: Bamford A, Turkova A, Lyall H, et al.; for PENTA Steering Committee
Published in: HIV Med. 2018;19(1):e1-e42.
Abstract The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade,
2018
Authors: Cotugno N, Morrocchi E, Pepponi I, et al.
Abstract Early initiation of ART in HIV vertically infected infants influences specific immunity by limiting Ag exposure and reducing the viral reservoir size. Currently these patients represent ideal candidates for testing immune therapeutic strategies towards HIV-remission.
2018
Authors: Collaborative Initiative for Paediatric HIV Education and Research (CHIPER) Global Cohort Collaboration
Published in: PLoS Med. 2018;15(3):e1002514.
Background Globally, the population of adolescents living with perinatally acquired HIV (APHs) continues to expand. In this study, we pooled data from observational pediatric HIV cohorts and cohort networks, allowing comparisons of adolescents with perinatally acquired HIV in “real-life” settings across multiple regions.
2018
Authors: Marotta C, Giaquinto C, Di Gennaro F, et al.
Published in: BMC Public Health. 2018;18(1):703.
Background In 2013, Mozambique implemented task-shifting (TS) from clinical officers to maternal and child nurses to improve care for HIV positive children < 5 years old. A retrospective, pre-post intervention study was designed to evaluate effectiveness of a new pathway of care in a sample of Beira District Local Health Facilities (LHFs),
2018
Authors: Ford D, Turner R, Turkova A, et al.
Published in: J Acquir Immune Defic Syndr. 2018;78(1):S40-S48.
Abstract For HIV-infected children, formulation development, pharmacokinetic (PK) data, and evaluation of early toxicity are critical for licensing new antiretroviral drugs; direct evidence of efficacy in children may not be needed if acceptable safety and PK parameters are demonstrated in children.
2018
Authors: Kawuma R, Seeley J, Mupambireyi Z, Cowan F, Bernays S; for REALITY Trial Team
Published in: Afr J AIDS Res. 2018;17(3):217-225
Abstract We examined the logic that individuals use to account for delaying HIV testing and/or initiating HIV treatment. Our qualitative study, situated within the REALITY trial (Reduction of EArly mortaLITY in HIV infected adults and children starting antiretroviral therapy),
2018
Authors: Tierrablanca LE, Ochalek J, Ford D, et al; for BREATHER (PENTA 16) Trial Group
Published in: Medicine (Baltimore). 2018;97(5):e9698
Objectives To analyze the cost effectiveness of short-cycle therapy (SCT), where patients take antiretroviral (ARV) drugs 5 consecutive days a week and have 2 days off, as an alternative to continuous ARV therapy for young people infected with human immunodeficiency virus (HIV) and taking efavirenz-based first-line ARV drugs.
2018
Authors: Turkova A, Moore CL, Butler K, et al. for BREATHER (PENTA 16) Trial Group.
Published in: PLos One. 2018;13(4):e0196239.
Background Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing lifelong treatment. BREATHER showed short cycle therapy (SCT; 5 days on, 2 days off ART) was non-inferior to continuous therapy (CT) over 48 weeks.
2018
Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial Team
Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22
2018
Authors: Moore CL, Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial Team
Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34
2018
Authors: Bernays S, Namukwaya S, Mupambireyi Z, Nanduudu A, Mujuru H, Turkova A, Gibb DM, Seeley J, and the ODYSSEY Trial Team.
Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st 2018. Poster number 117
2018
Authors: Turkova A, Bollen P, Kaudha E, et al. The ODYSSEY Trial Team
Published in: Oral Presentation at 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018
2018
Authors: Rinaldi S, Cotugno N, Pallikkuth S, Pahwa R, Palma P, Pahwa S
Abstract Early initiation of antiretroviral therapy (ART) in vertically HIV-infected children provides an opportunity to limit the size of HIV reservoir. However, how the time of ART initiation impacts host HIV-specific immune responses is still poorly understood.
2018
Authors: Violari A, Chan M, Otwombe KN, Panchia R, Jean-Philippe P, Gibb D, Cotton M, Babiker A
2018
Authors: Cameron M, Rinaldi S, Richardson B, Cotugno N, Williams S, Pallikkuth S, de Armas LR, Cameron C, Pahwa R, Palma P, Pahwa S
Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_868
Abstract The study explores the impact of early ART on host immune response looking at HIV-specific CD4 T cell functionality and host transcriptome analysis.
2018
Authors: Chan M, Tagarro A, Zangari P, Ferns B, Foster C, De Rossi A, Nastouli E, Ángeles Muñoz-Fernández M, Gibb D, Rossi P, Giaquinto C, Babiker A , Palma P, Rojo Conejo P
Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866
Abstract The study focused on the determinants of low viral reservoir in a large cohort of European early treated HIV-1 infected children.
2018
Authors: Bollen P, Colbers A, Schalkwijk S, Velthoven-Graafland K, Konopnicki D, Weizsacker K, Hidalgo Tenorio C, van Crevel R, Burger D, on behalf of the PANNA network
Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22nd-24th 2018, Baltimore
2018
Authors: Colbers A, Schalkwijk S, Konopnicki D, Rockstroh J, Burger D, on behalf of the PANNA network
Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22nd-24th 2018, Baltimore.
2018
Authors: Rocca S, Zangari P, Cotugno N, et al.
Published in: J Pediatric Infect Dis Soc.2018; 28. doi:10
Background Assays to estimate human immunodeficiency virus (HIV) reservoir size require large amounts of blood, which represents a drawback especially in pediatric settings. We investigated whether HIV-antibody repertoire could estimate the viral reservoir size. Moreover, we assessed the magnitude of HIV-antibody response as a predictor of time of antiretroviral therapy (ART) initiation.
2018
Authors: Cotugno N, Morrocchi E, Pepponi I, Rocca S, Cameron M, Rinaldi S, Di Cesare S, Pallikkuth S, Bernardi S, Klein N, Ananworanich J, Rossi P, Pahwa S, Palma P
Published: 25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866
Abstract This fascinating study investigates whether HIV specific B cells persist in seronegative HIV infected seronegative patients and what are the associated gene signatures after re-encountering the virus.
2018
Authors: Tagarro A, Chan M, Zangari P, et al; on behalf of the EPIICAL Consortium
Published in: J Acquir Immune Defic Syndr. 2018;79(2):269-276
Background Future strategies aiming to achieve HIV-1 remission are likely to target individuals with small reservoir size.
Setting We retrospectively investigated factors associated with HIV-1 DNA levels in European,
2018
Authors: Judd A, Chappell E, Turkova A; for European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord.
Published in: PLoS Med. 2018;15(1): e1002491
Background Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries,
2018
Authors: IeDEA and COHERE Cohort Collaborations.
Published in: Clin Infect Dis. 2018;66(6):893-903.
Background Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progression and reduces sexual transmission of human immunodeficiency virus (HIV). We describe the temporal trends in CD4 cell counts at the start of cART in adults from low-income,